– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of...
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share....
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date observed for patients who have reached CR – – All subsequently enrolled patients for whom MRD results are available are MRD-negative at one...
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY....
– Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded Chief Medical Officer, formerly of Merck and Johnson & Johnson for BLA submission – LOS ANGELES, CA, March 30, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc....
LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host investor meetings at the following upcoming institutional investor conferences:...
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this year followed by planned BLA submission – LOS ANGELES, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc....
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of...
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in...
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 95% – – NEXICART-2 final readout and BLA submission planned in 2026 – LOS ANGELES, CA,...